InDevR
InDevR develops multiplexed microarray immunoassay kits and automated analyzers that enable vaccine manufacturers, mRNA developers, and research labs to perform rapid potency, identity, and quality control testing, selling through direct enterprise sales and exclusive European distribution partners bioMérieux and I&L Biosystems.
- Company typePrivate
- Founded2003
- HeadquartersBoulder, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What InDevR does
InDevR is a Boulder, Colorado-based life science tools company founded in 2003 that develops and commercializes microarray-based analytical solutions for vaccine and biotherapeutic characterization, potency testing, and quality control release. The company's core platform, VaxArray, is a multiplexed microarray immunoassay system that enables simultaneous quantification of more than 50 analytes per well across 24-well slides, producing results in under two hours versus the days required by traditional single-plex methods such as ELISA, SRID, flow cytometry, HPLC, and Luminex. InDevR's product portfolio includes ready-to-go reagent kits for seasonal and pandemic influenza (OmniFlu HA, OmniFlu HA/NA 96, pandemic H5/H7/H9 kits), a 23-valent pneumococcal serotyping kit developed with Bill & Melinda Gates Foundation support, a coronavirus serology kit, the 5'CapQ assay for rapid mRNA capping efficiency and integrity testing without extraction, and the CypherOne automated hemagglutination analyzer with 21 CFR Part 11 compliant software.
The company sells primarily to enterprise vaccine manufacturers (pharmaceutical and biotech), mRNA and cell/gene therapy developers, academic and government research labs, and contract research organizations, with named customers including CSL (Seqirus), Aldevron, QPS, Inventprise, Vaxess Technologies, Solaris Vaccines, and Colorado State University. InDevR monetizes through sales of reagent kits and instrumentation, supplemented by a higher-margin Expert Services line that delivers custom assay development. The go-to-market combines an enterprise field sales team with exclusive distribution partnerships: bioMérieux holds exclusive European rights for the VaxArray portfolio (since January 2023 with a board seat), and I&L Biosystems provides sales and support across Germany, Netherlands, France, and the UK. The company has historically relied heavily on non-dilutive funding, accumulating approximately $45M in government and foundation grants and contracts (including a $14.7M BARDA contract for FluChip-8G), alongside a $9M Series B in January 2023 from Adjuvant Capital and bioMérieux. In February 2026, SSI Diagnostica Group (Copenhagen) acquired InDevR, integrating it as a wholly owned affiliate within its Life Science Solutions portfolio.
InDevR firmographics
Firmographics- Name
- InDevR
- Legal name
- InDevR, Inc.
- Website
- https://indevr.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- InDevR develops multiplexed microarray immunoassay kits and automated analyzers that enable vaccine manufacturers, mRNA developers, and research labs to perform rapid potency, identity, and quality control testing, selling through direct enterprise sales and exclusive European distribution partners bioMérieux and I&L Biosystems.
- Ownership category
- akta.pro rank
Where InDevR is headquartered
LocationHeadquarters
- HQ city
- Boulder
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
InDevR business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- VaxArray Product Kits: Sale of ready-to-go reagent kits for the VaxArray platform including influenza kits (OmniFlu HA, OmniFlu HA/NA 96), pneumococcal kits, coronavirus kits, 5'CapQ assay, and custom multiplexed assay kits.
- CypherOne Instrument: Sale of automated hemagglutination analyzer instrumentation.
- Expert Services: Custom assay development and testing services. Expert Services team develops customized microarray assays for customers to address specific vaccine characterization needs, eliminating development bottlenecks.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Annual | Microarray Scientist position |
| Other | Hourly | Expert Services Laboratory Associate I position |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
InDevR product offering
Product offeringCore offering
InDevR develops and manufactures microarray-based multiplexed immunoassay kits and automated instruments under the VaxArray and CypherOne brands for vaccine potency testing, characterization, and quality control release. Its products are used by pharmaceutical and biotech vaccine manufacturers, mRNA and cell/gene therapy developers, CROs, and research labs to quantify multiple antigens or analytes in a single test with results in under 2 hours. The company also provides Expert Services for custom microarray assay development.
Differentiator
Problem solved
Functional benefit
Brands
- VaxArray: Multiplexed microarray platform for vaccine potency testing and analytical characterization of vaccines and biotherapeutics
- CypherOne
- 5'CapQ
- OmniFlu HA/NA
- Expert Services
Products and services
- VaxArray Platform Multiplexed microarray immunoassay platform for vaccine potency testing, antigen/antibody quantification, serology, and quality control release testing across seasonal influenza, pneumococcal, mRNA, and other vaccine types. Used by vaccine manufacturers, mRNA and cell/gene therapy developers, CROs, and research labs.
- CypherOne System
Quantifiable outcome
- Time to result: 2 hours vs. 48 hours for SRID (gold standard)
- +3 more outcomes
Companies that use InDevR
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles4 records
InDevR technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
InDevR partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and strategic.
- SSI Diagnostica GroupcoreSSI Diagnostica Group, a Copenhagen-based company specializing in infectious disease testing solutions, acquired InDevR in February 2026. The acquisition strengthens SSI Diagnostica's leadership in pneumococcal vaccine QC testing while adding InDevR's expertise in influenza and mRNA vaccine QC testing to its Life Science portfolio.
- Sino BiologicalstrategicPartnership to speed development of multiplexed assays for mRNA vaccines and cell and gene therapy applications. Sino Biological's catalog of high-quality antibodies, antigens, and reagents available for use on InDevR's VaxArray Platform.
- PATH (Program for Appropriate Technology in Health)strategicPATH and partners developed monoclonal capture antibodies for VaxArray Pneumococcal Assay. Antibodies made available to industry through repository at MHRA site in South Mimms, UK (NIBSC standards).
- Mount Sinai (Icahn School of Medicine)coreExclusive worldwide license agreement for anti-neuraminidase monoclonal antibodies for rapid, subtype-specific quantification of neuraminidase in the multiplexed VaxArray system. Antibodies developed by Mount Sinai scientists.
- FDA (U.S. Food and Drug Administration)strategicJoint publication with FDA on Cypher One automated hemagglutination analyzer. Study 'Automated interpretation of influenza hemagglutination inhibition (HAI) assays' published in PLOS ONE showing 95% agreement between Cypher One and expert human readers.
- I&L BiosystemscoreExclusive sales, marketing and customer support relationship for Cypher One and VaxArray product lines throughout Western Europe. I&L Biosystems has subsidiaries in Germany, Netherlands, France, and UK with native language support.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
InDevR competitors and assessment
Company assessmentBroad incumbents
- Sartorius: Provides bioprocess analytics and virus quantification tools used in vaccine manufacturing release, overlapping with InDevR's potency testing focus.
- Bio-Rad Laboratories: Major life sciences tools company whose Bio-Plex multiplex bead-based immunoassay platform directly competes with VaxArray in vaccine and biologics characterization workflows.
- Charles River Laboratories: Contract research and vaccine safety/potency testing services and products address the same vaccine manufacturer QC customers as InDevR.
- Repligen: Supplies analytics and process solutions for biologic and vaccine manufacturing, including analytical instruments used in QC release workflows.
- PerkinElmer: Broad life sciences analytics portfolio (including Eurofins-acquired cell and gene therapy tools) covers vaccine and biotherapeutic QC workflows that overlap with InDevR's offerings.
Direct peers
- Meso Scale Diagnostics: Developer of multiplex electrochemiluminescence immunoassay platforms widely used for vaccine potency and serology applications, offering overlapping functionality to InDevR's VaxArray.
- Luminex (DiaSorin): Multiplex bead-based assay systems (MAGPIX, FLEXMAP 3D) used for vaccine and biologics analytics, now part of DiaSorin; competes with VaxArray's multiplexing approach.
- Cygnus Technologies: Specializes in host cell protein and bioprocess impurity detection assays for vaccine and biologic manufacturing, sharing the biopharma QC customer base.
Emerging players
- Gyros Protein Technologies: Provides immunoassay and quantification platforms for biologics development and manufacturing, offering parallel microanalytical capabilities to VaxArray.
- Molecular Devices: Microplate readers and cell-based assay instruments used in vaccine potency and bioassay workflows, complementary to microarray-based VaxArray.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
InDevR social profiles
Digital presenceInDevR financial estimates
Financial estimateRevenue estimate
Valuation estimate
InDevR leadership team
Management profileNumber of profiles
Profiles8 records
InDevR funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InDevR M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InDevR
What does InDevR do?
InDevR develops and manufactures microarray-based multiplexed immunoassay kits and automated instruments under the VaxArray and CypherOne brands for vaccine potency testing, characterization, and quality control release. Its products are used by pharmaceutical and biotech vaccine manufacturers, mRNA and cell/gene therapy developers, CROs, and research labs to quantify multiple antigens or analytes in a single test with results in under 2 hours. The company also provides Expert Services for custom microarray assay development.
Is InDevR a public or private company?
InDevR is a private company. It is classified as corporate owned and is currently acquired.
When was InDevR founded?
InDevR was founded in 2003. It employs 11 to 50 people.
Where is InDevR based?
InDevR is headquartered in Boulder, United States, in the North America region.
How does InDevR make money?
Three revenue lines are on record. VaxArray Product Kits are the primary driver. The others are cypherOne Instrument and expert Services.
Who are InDevR's main competitors?
Broad incumbents on record are Sartorius, Bio-Rad Laboratories, Charles River Laboratories, Repligen and PerkinElmer. Direct peers are Meso Scale Diagnostics, Luminex (DiaSorin) and Cygnus Technologies. Emerging players are Gyros Protein Technologies and Molecular Devices.
Does InDevR have an API?
No public API is recorded for InDevR.